Bioactive compounds and their derivatives: an insight into prospective phytotherapeutic approach against alzheimer's disease
F Islam, JF Khadija, M Harun-Or-Rashid… - Oxidative Medicine …, 2022 - Wiley Online Library
Alzheimer's disease (AD) is a common neurodegenerative brain disorder that causes
cellular response alterations, such as impaired cholinergic mechanism, amyloid‐beta (Aβ) …
cellular response alterations, such as impaired cholinergic mechanism, amyloid‐beta (Aβ) …
Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's disease
J Sheng, S Zhang, L Wu, G Kumar, Y Liao… - Frontiers in Aging …, 2022 - frontiersin.org
Alzheimer's disease (AD) is the most common form of dementia and is ranked as the 6th
leading cause of death in the US. The prevalence of AD and dementia is steadily increasing …
leading cause of death in the US. The prevalence of AD and dementia is steadily increasing …
[PDF][PDF] Inhibition of phosphodiesterase: A novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's
J Sheng, S Zhang, GK Lule Wu, Y Liao, GK Pratap… - 2022 - academia.edu
Alzheimer's disease (AD) is a neurodegenerative cognitive disorder affecting around 36
million individuals around the world. By 2050, this number is expected to quadruple …
million individuals around the world. By 2050, this number is expected to quadruple …